Cargando…

Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations

Detalles Bibliográficos
Autor principal:	Milano, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965481/ https://www.ncbi.nlm.nih.gov/pubmed/27312734 http://dx.doi.org/10.1007/s00280-016-3081-z

Ejemplares similares

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
por: Schneider, Bryan P, et al.
Publicado: (2009)

Human Platelets Take up Anti-VEGF Agents
por: Sobolewska, B., et al.
Publicado: (2021)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered
por: Hanhart, Joel, et al.
Publicado: (2023)

Recent developments on potential new applications of emetine as anti-cancer agent
por: Uzor, Philip F.
Publicado: (2016)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Expanding the horizon of costoclavicular block – shouldering new responsibility!
por: Sonawane, Kartik, et al.
Publicado: (2021)

Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Ålgars, A, et al.
Publicado: (2012)

Orocrinology: Expanding the Horizon
por: Balachandran, Karthik, et al.
Publicado: (2020)

Cardiothoracic Imaging in China: Opening Up New Horizons
por: Zhang, Long Jiang, et al.
Publicado: (2022)

Wisdom quotes and psychological well-being: A new horizon
por: Shamim, Thorakkal
Publicado: (2022)

Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia
por: Fodstad, Philip, et al.
Publicado: (2010)

Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

Can we use Tramadol as an anti-shivering agent?
por: Joshi, Chhaya, et al.
Publicado: (2012)

Anticoagulants and Anti-platelet Agents in Palliative Home Healthcare
por: Wiwanitkit, Viroj
Publicado: (2011)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion
por: Acencio, Milena Marques Pagliarelli, et al.
Publicado: (2017)

The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury
por: Zhao, Xiao, et al.
Publicado: (2021)

Anti-VEGF Agents and Glaucoma Filtering Surgery
por: Daneshvar, Ramin
Publicado: (2013)

Use of Anti-VEGF Agents in Glaucoma Surgery
por: Slabaugh, Mark, et al.
Publicado: (2017)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent
por: Su, Er-Ning, et al.
Publicado: (2012)

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
por: Park, Young Gun, et al.
Publicado: (2012)

Management of anti-VEGF intravitreal treatment at University Hospital Federico II of Naples during COVID-19 pandemic lockdown
por: Comune, Chiara, et al.
Publicado: (2020)

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Lopez-Crapez, E, et al.
Publicado: (2010)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Iron overload and fragmented QRS in patients with Thalassemia major: Mechanisms, therapies, and new horizons
por: Karakulak, Uğur Nadir, et al.
Publicado: (2015)

mTOR inhibitors: A novel class of anti-cancer agents
por: Riaz, Haris, et al.
Publicado: (2012)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Fermilab opens new horizons
Publicado: (1985)

Does anti-VEGF bevacizumab improve survival in experimental sepsis?
por: Besnier, Emmanuel, et al.
Publicado: (2017)

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Cremolini, C, et al.
Publicado: (2010)

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability
por: Kimoto, Kenichi, et al.
Publicado: (2012)

Quantifying Conflict of Interest in the Choice of Anti-VEGF Agents
por: Browning, David J, et al.
Publicado: (2021)

The role of Anti-VEGF agents in treatment of neovascular glaucoma
por: Palfi (Salavat), Mădălina-Casiana, et al.
Publicado: (2022)

Pirfenidone; can it be a new horizon for the treatment of pulmonary fibrosis in mustard gas-intoxicated patients?
por: Zamani, Nasim
Publicado: (2013)

New landscapes and horizons in hepatocellular carcinoma therapy
por: Cervello, Melchiorre, et al.
Publicado: (2020)

Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS
por: Spanopoulou, Christina, et al.
Publicado: (2020)

Baclofen from an ‘anti-craving’ agent to ‘craved for’ drug: A case report
por: Sharma, Rachit, et al.
Publicado: (2023)

Cure for HIV: New possibility on horizon
por: Singh, Anchal, et al.
Publicado: (2011)

Medicine at nanoscale: a new horizon
por: Khan, Asad U
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1kb1vr30692ghrbfpa2i4of974